Cancer and Metastasis Reviews最新文献_第10页

Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy. T 细胞表观遗传学重编程：开启癌症免疫疗法的新途径。

IF 9.2 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-03-01 Epub Date: 2024-01-18 DOI: 10.1007/s10555-024-10167-w

Vipin Singh, Sandhik Nandi, Aritra Ghosh, Santanu Adhikary, Shravanti Mukherjee, Siddhartha Roy, Chandrima Das

{"title":"Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy.","authors":"Vipin Singh, Sandhik Nandi, Aritra Ghosh, Santanu Adhikary, Shravanti Mukherjee, Siddhartha Roy, Chandrima Das","doi":"10.1007/s10555-024-10167-w","DOIUrl":"10.1007/s10555-024-10167-w","url":null,"abstract":"T cells, a key component of cancer immunotherapy, undergo a variety of histone modifications and DNA methylation changes since their bone marrow progenitor stages before developing into CD8+ and CD4+ T cells. These T cell types can be categorized into distinct subtypes based on their functionality and properties, such as cytotoxic T cells (Tc), helper T cells (Th), and regulatory T cells (Treg) as subtypes for CD8+ and CD4+ T cells. Among these, the CD4+ CD25+ Tregs potentially contribute to cancer development and progression by lowering T effector (Teff) cell activity under the influence of the tumor microenvironment (TME). This contributes to the development of therapeutic resistance in patients with cancer. Subsequently, these individuals become resistant to monoclonal antibody therapy as well as clinically established immunotherapies. In this review, we delineate the different epigenetic mechanisms in cancer immune response and its involvement in therapeutic resistance. Furthermore, the possibility of epi-immunotherapeutic methods based on histone deacetylase inhibitors and histone methyltransferase inhibitors are under investigation. In this review we highlight EZH2 as the principal driver of cancer cell immunoediting and an immune escape regulator. We have addressed in detail how understanding T cell epigenetic regulation might bring unique inventive strategies to overcome drug resistance and increase the efficacy of cancer immunotherapy.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"175-195"},"PeriodicalIF":9.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139484341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation. 前列腺癌耐药性的分子全景：临床前和生物信息学分析促进临床转化。

IF 9.2 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-03-01 Epub Date: 2024-02-19 DOI: 10.1007/s10555-024-10168-9

Milad Ashrafizadeh, Wei Zhang, Yu Tian, Gautam Sethi, Xianbin Zhang, Aiming Qiu

{"title":"Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.","authors":"Milad Ashrafizadeh, Wei Zhang, Yu Tian, Gautam Sethi, Xianbin Zhang, Aiming Qiu","doi":"10.1007/s10555-024-10168-9","DOIUrl":"10.1007/s10555-024-10168-9","url":null,"abstract":"Prostate cancer (PCa) is a malignant disorder of prostate gland being asymptomatic in early stages and high metastatic potential in advanced stages. The chemotherapy and surgical resection have provided favourable prognosis of PCa patients, but advanced and aggressive forms of PCa including CRPC and AVPC lack response to therapy properly, and therefore, prognosis of patients is deteriorated. At the advanced stages, PCa cells do not respond to chemotherapy and radiotherapy in a satisfactory level, and therefore, therapy resistance is emerged. Molecular profile analysis of PCa cells reveals the apoptosis suppression, pro-survival autophagy induction, and EMT induction as factors in escalating malignant of cancer cells and development of therapy resistance. The dysregulation in molecular profile of PCa including upregulation of STAT3 and PI3K/Akt, downregulation of STAT3, and aberrant expression of non-coding RNAs are determining factor for response of cancer cells to chemotherapy. Because of prevalence of drug resistance in PCa, combination therapy including co-utilization of anti-cancer drugs and nanotherapeutic approaches has been suggested in PCa therapy. As a result of increase in DNA damage repair, PCa cells induce radioresistance and RelB overexpression prevents irradiation-mediated cell death. Similar to chemotherapy, nanomaterials are promising for promoting radiosensitivity through delivery of cargo, improving accumulation in PCa cells, and targeting survival-related pathways. In respect to emergence of immunotherapy as a new tool in PCa suppression, tumour cells are able to increase PD-L1 expression and inactivate NK cells in mediating immune evasion. The bioinformatics analysis for evaluation of drug resistance-related genes has been performed.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"229-260"},"PeriodicalIF":9.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting the key players of phenotypic plasticity in cancer cells by phytochemicals. 利用植物化学物质靶向癌细胞表型可塑性的关键角色。

IF 9.2 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-03-01 Epub Date: 2024-01-03 DOI: 10.1007/s10555-023-10161-8

Sajad Fakhri, Seyed Zachariah Moradi, Fatemeh Abbaszadeh, Farahnaz Faraji, Roshanak Amirian, Dona Sinha, Emily G McMahon, Anupam Bishayee

{"title":"Targeting the key players of phenotypic plasticity in cancer cells by phytochemicals.","authors":"Sajad Fakhri, Seyed Zachariah Moradi, Fatemeh Abbaszadeh, Farahnaz Faraji, Roshanak Amirian, Dona Sinha, Emily G McMahon, Anupam Bishayee","doi":"10.1007/s10555-023-10161-8","DOIUrl":"10.1007/s10555-023-10161-8","url":null,"abstract":"Plasticity of phenotypic traits refers to an organism's ability to change in response to environmental stimuli. As a result, the response may alter an organism's physiological state, morphology, behavior, and phenotype. Phenotypic plasticity in cancer cells describes the considerable ability of cancer cells to transform phenotypes through non-genetic molecular signaling activities that promote therapy evasion and tumor metastasis via amplifying cancer heterogeneity. As a result of metastable phenotypic state transitions, cancer cells can tolerate chemotherapy or develop transient adaptive resistance. Therefore, new findings have paved the road in identifying factors and agents that inhibit or suppress phenotypic plasticity. It has also investigated novel multitargeted agents that may promise new effective strategies in cancer treatment. Despite the efficiency of conventional chemotherapeutic agents, drug toxicity, development of resistance, and high-cost limit their use in cancer therapy. Recent research has shown that small molecules derived from natural sources are capable of suppressing cancer by focusing on the plasticity of phenotypic responses. This systematic, comprehensive, and critical review analyzes the current state of knowledge regarding the ability of phytocompounds to target phenotypic plasticity at both preclinical and clinical levels. Current challenges/pitfalls, limitations, and future perspectives are also discussed.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"261-292"},"PeriodicalIF":9.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies. 非编码 RNA 对 HIF-1α 的严格调控：关于增殖、转移和治疗抗性策略的新见解。

IF 9.2 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-03-01 Epub Date: 2023-08-08 DOI: 10.1007/s10555-023-10129-8

Sabrean Farhan Jawad, Farag M A Altalbawy, Radhwan M Hussein, Ali Abdulhussain Fadhil, Mohammed Abed Jawad, Rahman S Zabibah, Tasneem Younus Taraki, Chakrabhavi Dhananjaya Mohan, Kanchugarakoppal S Rangappa

{"title":"The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies.","authors":"Sabrean Farhan Jawad, Farag M A Altalbawy, Radhwan M Hussein, Ali Abdulhussain Fadhil, Mohammed Abed Jawad, Rahman S Zabibah, Tasneem Younus Taraki, Chakrabhavi Dhananjaya Mohan, Kanchugarakoppal S Rangappa","doi":"10.1007/s10555-023-10129-8","DOIUrl":"10.1007/s10555-023-10129-8","url":null,"abstract":"The hypoxic environment is prominently witnessed in most solid tumors and is associated with the promotion of cell proliferation, epithelial-mesenchymal transition (EMT), angiogenesis, metabolic reprogramming, therapeutic resistance, and metastasis of tumor cells. All the effects are mediated by the expression of a transcription factor hypoxia-inducible factor-1α (HIF-1α). HIF-1α transcriptionally modulates the expression of genes responsible for all the aforementioned functions. The stability of HIF-1α is regulated by many proteins and non-coding RNAs (ncRNAs). In this article, we have critically discussed the crucial role of ncRNAs [such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), Piwi-interacting RNAs (piRNAs), and transfer RNA (tRNA)-derived small RNAs (tsRNAs)] in the regulation of stability and expression of HIF-1α. We have comprehensively discussed the molecular mechanisms and relationship of HIF-1α with each type of ncRNA in either promotion or repression of human cancers and therapeutic resistance. We have also elaborated on ncRNAs that are in clinical examination for the treatment of cancers. Overall, the majority of aspects concerning the relationship between HIF-1α and ncRNAs have been discussed in this article.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"5-27"},"PeriodicalIF":9.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9952167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Resveratrol as sensitizer in colorectal cancer plasticity. 白藜芦醇是结直肠癌可塑性的增敏剂。

IF 9.2 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-03-01 Epub Date: 2023-07-29 DOI: 10.1007/s10555-023-10126-x

Aranka Brockmueller, Anjana Sajeev, Lenka Koklesova, Samson Mathews Samuel, Peter Kubatka, Dietrich Büsselberg, Ajaikumar B Kunnumakkara, Mehdi Shakibaei

{"title":"Resveratrol as sensitizer in colorectal cancer plasticity.","authors":"Aranka Brockmueller, Anjana Sajeev, Lenka Koklesova, Samson Mathews Samuel, Peter Kubatka, Dietrich Büsselberg, Ajaikumar B Kunnumakkara, Mehdi Shakibaei","doi":"10.1007/s10555-023-10126-x","DOIUrl":"10.1007/s10555-023-10126-x","url":null,"abstract":"Despite tremendous medical treatment successes, colorectal cancer (CRC) remains a leading cause of cancer deaths worldwide. Chemotherapy as monotherapy can lead to significant side effects and chemoresistance that can be linked to several resistance-activating biological processes, including an increase in inflammation, cellular plasticity, multidrug resistance (MDR), inhibition of the sentinel gene p53, and apoptosis. As a consequence, tumor cells can escape the effectiveness of chemotherapeutic agents. This underscores the need for cross-target therapeutic approaches that are not only pharmacologically safe but also modulate multiple potent signaling pathways and sensitize cancer cells to overcome resistance to standard drugs. In recent years, scientists have been searching for natural compounds that can be used as chemosensitizers in addition to conventional medications for the synergistic treatment of CRC. Resveratrol, a natural polyphenolic phytoalexin found in various fruits and vegetables such as peanuts, berries, and red grapes, is one of the most effective natural chemopreventive agents. Abundant in vitro and in vivo studies have shown that resveratrol, in interaction with standard drugs, is an effective chemosensitizer for CRC cells to chemotherapeutic agents and thus prevents drug resistance by modulating multiple pathways, including transcription factors, epithelial-to-mesenchymal transition-plasticity, proliferation, metastasis, angiogenesis, cell cycle, and apoptosis. The ability of resveratrol to modify multiple subcellular pathways that may suppress cancer cell plasticity and reversal of chemoresistance are critical parameters for understanding its anti-cancer effects. In this review, we focus on the chemosensitizing properties of resveratrol in CRC and, thus, its potential importance as an additive to ongoing treatments.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"55-85"},"PeriodicalIF":9.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11016130/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10264333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments 大肠癌：致癌、诊断和分类治疗新策略的全面回顾

IF 9.2 2区医学

Cancer and Metastasis Reviews Pub Date : 2023-12-19 DOI: 10.1007/s10555-023-10158-3

Roya Abedizadeh, Fateme Majidi, Hamid Reza Khorasani, Hassan Abedi, Davood Sabour

{"title":"Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments","authors":"Roya Abedizadeh, Fateme Majidi, Hamid Reza Khorasani, Hassan Abedi, Davood Sabour","doi":"10.1007/s10555-023-10158-3","DOIUrl":"https://doi.org/10.1007/s10555-023-10158-3","url":null,"abstract":"Colorectal cancer is the third most common and the second deadliest cancer worldwide. To date, colorectal cancer becomes one of the most important challenges of the health system in many countries. Since the clinical symptoms of this cancer appear in the final stages of the disease and there is a significant golden time between the formation of polyps and the onset of cancer, early diagnosis can play a significant role in reducing mortality. Today, in addition to colonoscopy, minimally invasive methods such as liquid biopsy have received much attention. The treatment of this complex disease has been mostly based on traditional treatments including surgery, radiotherapy, and chemotherapy; the high mortality rate indicates a lack of success for current treatment methods. Moreover, disease recurrence is another problem of traditional treatments. Recently, new approaches such as targeted therapy, immunotherapy, and nanomedicine have opened new doors for cancer treatment, some of which have already entered the market, and many methods have shown promising results in clinical trials. The success of immunotherapy in the treatment of refractory disease, the introduction of these methods into neoadjuvant therapy, and the successful results in tumor shrinkage without surgery have made immunotherapy a tough competitor for conventional treatments. It seems that the combination of those methods with such targeted therapies will go through promising changes in the future of colorectal cancer treatment.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":"38 1","pages":""},"PeriodicalIF":9.2,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138743162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biography—Mathieu Boissan, Pharm.D., Ph.D 简历-马蒂厄-博瓦桑，药学博士，博士生导师

IF 9.2 2区医学

Cancer and Metastasis Reviews Pub Date : 2023-12-11 DOI: 10.1007/s10555-023-10143-w

引用次数: 0

HOXA9 transcription factor is a double-edged sword: from development to cancer progression HOXA9转录因子是一把双刃剑：从发育到癌症进展

IF 9.2 2区医学

Cancer and Metastasis Reviews Pub Date : 2023-12-08 DOI: 10.1007/s10555-023-10159-2

U Sangeetha Shenoy, Divya Adiga, Faisal Alhedyan, Shama Prasada Kabekkodu, Raghu Radhakrishnan

{"title":"HOXA9 transcription factor is a double-edged sword: from development to cancer progression","authors":"U Sangeetha Shenoy, Divya Adiga, Faisal Alhedyan, Shama Prasada Kabekkodu, Raghu Radhakrishnan","doi":"10.1007/s10555-023-10159-2","DOIUrl":"https://doi.org/10.1007/s10555-023-10159-2","url":null,"abstract":"The HOXA9 transcription factor serves as a molecular orchestrator in cancer stemness, epithelial-mesenchymal transition (EMT), metastasis, and generation of the tumor microenvironment in hematological and solid malignancies. However, the multiple modes of regulation, multifaceted functions, and context-dependent interactions responsible for the dual role of HOXA9 as an oncogene or tumor suppressor in cancer remain obscure. Hence, unravelling its molecular complexities, binding partners, and interacting signaling molecules enables us to comprehend HOXA9-mediated transcriptional programs and molecular crosstalk. However, it is imperative to understand its central role in fundamental biological processes such as embryogenesis, foetus implantation, hematopoiesis, endothelial cell proliferation, and tissue homeostasis before designing targeted therapies. Indeed, it presents an enormous challenge for clinicians to selectively target its oncogenic functions or restore tumor-suppressive role without altering normal cellular functions. In addition to its implications in cancer, the present review also focuses on the clinical applications of HOXA9 in recurrence and drug resistance, which may provide a broader understanding beyond oncology, open new avenues for clinicians for accurate diagnoses, and develop personalized treatment strategies. Furthermore, we have also discussed the existing therapeutic options and accompanying challenges in HOXA9-targeted therapies in different cancer types.<h3 data-test=\"abstract-sub-heading\">Graphical Abstract</h3>","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":"26 1","pages":""},"PeriodicalIF":9.2,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138553951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Carcinoma of unknown primary (CUP): an update for histopathologists. 原发灶不明的癌症（CUP）：组织病理学家的最新进展。

IF 9.2 2区医学

Cancer and Metastasis Reviews Pub Date : 2023-12-01 Epub Date: 2023-07-03 DOI: 10.1007/s10555-023-10101-6

Katie Beauchamp, Bruce Moran, Timothy O'Brien, Donal Brennan, John Crown, Kieran Sheahan, Maura Bríd Cotter

{"title":"Carcinoma of unknown primary (CUP): an update for histopathologists.","authors":"Katie Beauchamp, Bruce Moran, Timothy O'Brien, Donal Brennan, John Crown, Kieran Sheahan, Maura Bríd Cotter","doi":"10.1007/s10555-023-10101-6","DOIUrl":"10.1007/s10555-023-10101-6","url":null,"abstract":"Carcinoma of unknown primary (CUP) is a heterogeneous group of metastatic cancers in which the site of origin is not identifiable. These carcinomas have a poor outcome due to their late presentation with metastatic disease, difficulty in identifying the origin and delay in treatment. The aim of the pathologist is to broadly classify and subtype the cancer and, where possible, to confirm the likely primary site as this information best predicts patient outcome and guides treatment. In this review, we provide histopathologists with diagnostic practice points which contribute to identifying the primary origin in such cases. We present the current clinical evaluation and management from the point of view of the oncologist. We discuss the role of the pathologist in the diagnostic pathway including the control of pre-analytical conditions, assessment of sample adequacy, diagnosis of cancer including diagnostic pitfalls, and evaluation of prognostic and predictive markers. An integrated diagnostic report is ideal in cases of CUP, with results discussed at a forum such as a molecular tumour board and matched with targeted treatment. This highly specialized evolving area ultimately leads to personalized oncology and potentially improved outcomes for patients.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1189-1200"},"PeriodicalIF":9.2,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10713813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9737170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Helicobacter pylori-activated fibroblasts as a silent partner in gastric cancer development. 幽门螺杆菌激活的成纤维细胞是胃癌发展过程中的沉默伙伴

IF 9.2 2区医学

Cancer and Metastasis Reviews Pub Date : 2023-12-01 Epub Date: 2023-07-17 DOI: 10.1007/s10555-023-10122-1

Gracjana Krzysiek-Maczka, Tomasz Brzozowski, Agata Ptak-Belowska

{"title":"Helicobacter pylori-activated fibroblasts as a silent partner in gastric cancer development.","authors":"Gracjana Krzysiek-Maczka, Tomasz Brzozowski, Agata Ptak-Belowska","doi":"10.1007/s10555-023-10122-1","DOIUrl":"10.1007/s10555-023-10122-1","url":null,"abstract":"The discovery of Helicobacter pylori (Hp) infection of gastric mucosa leading to active chronic gastritis, gastroduodenal ulcers, and MALT lymphoma laid the groundwork for understanding of the general relationship between chronic infection, inflammation, and cancer. Nevertheless, this sequence of events is still far from full understanding with new players and mediators being constantly identified. Originally, the Hp virulence factors affecting mainly gastric epithelium were proposed to contribute considerably to gastric inflammation, ulceration, and cancer. Furthermore, it has been shown that Hp possesses the ability to penetrate the mucus layer and directly interact with stroma components including fibroblasts and myofibroblasts. These cells, which are the source of biophysical and biochemical signals providing the proper balance between cell proliferation and differentiation within gastric epithelial stem cell compartment, when exposed to Hp, can convert into cancer-associated fibroblast (CAF) phenotype. The crosstalk between fibroblasts and myofibroblasts with gastric epithelial cells including stem/progenitor cell niche involves several pathways mediated by non-coding RNAs, Wnt, BMP, TGF-β, and Notch signaling ligands. The current review concentrates on the consequences of Hp-induced increase in gastric fibroblast and myofibroblast number, and their activation towards CAFs with the emphasis to the altered communication between mesenchymal and epithelial cell compartment, which may lead to inflammation, epithelial stem cell overproliferation, disturbed differentiation, and gradual gastric cancer development. Thus, Hp-activated fibroblasts may constitute the target for anti-cancer treatment and, importantly, for the pharmacotherapies diminishing their activation particularly at the early stages of Hp infection.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1219-1256"},"PeriodicalIF":9.2,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10713772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9882087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0